Clinical trials recruiting in Sayama, Japan

Phase breakdown

Conditions recruiting in Sayama, Japan

Recruiting trials in Sayama, Japan

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
  NCT05967689 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
  NCT05392764 · Phase: Phase 3 · Ages: 20 Years and older · Sex: All (male and female)
• TheraSphere Japan Pre-Market Study
  NCT07377487 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Sayama, Japan?

4 recruiting trials have at least one study site in Sayama, Japan.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.